Your browser doesn't support javascript.
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2.
Scott, Tristan A; Supramaniam, Aroon; Idris, Adi; Cardoso, Angelo A; Shrivastava, Surya; Kelly, Gabrielle; Grepo, Nicole A; Soemardy, Citradewi; Ray, Roslyn M; McMillan, Nigel A J; Morris, Kevin V.
  • Scott TA; Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
  • Supramaniam A; Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Brisbane 4222, Australia.
  • Idris A; Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Brisbane 4222, Australia.
  • Cardoso AA; Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
  • Shrivastava S; Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
  • Kelly G; Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Brisbane 4222, Australia.
  • Grepo NA; Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
  • Soemardy C; Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
  • Ray RM; Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute at the City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
  • McMillan NAJ; Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Brisbane 4222, Australia.
  • Morris KV; Menzies Health Institute Queensland, School of Pharmacy and Medical Science, Griffith University, Gold Coast Campus, Brisbane 4222, Australia.
Mol Ther Methods Clin Dev ; 24: 355-366, 2022 Mar 10.
Article in English | MEDLINE | ID: covidwho-1665331
ABSTRACT
SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to neutralize SARS-CoV-2, which consists of extracellular vesicles (EVs) containing a novel fusion tetraspanin protein, CD63, embedded within an anti-CoV-2 nanobody. These anti-CoV-2-enriched EVs bind SARS-CoV-2 spike protein at the receptor-binding domain (RBD) site and can functionally neutralize SARS-CoV-2. This work demonstrates an innovative EV-targeting platform that can be employed to target and inhibit the early stages of SARS-CoV-2 infection.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Mol Ther Methods Clin Dev Year: 2022 Document Type: Article Affiliation country: J.omtm.2022.01.015

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Journal: Mol Ther Methods Clin Dev Year: 2022 Document Type: Article Affiliation country: J.omtm.2022.01.015